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BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) is an
agent which increases the affinity of haemoglobin for oxygen by
stabilizing oxyhaemoglobin in a dose-dependent manner (Beddell
et al, 1984). This results in a left-shift in the haemoglobin oxygen
saturation curve (OSC), thereby reducing oxygen dissociation at
low partial oxygen pressures and so reducing tissue oxygen
delivery. The effect of BW12C on oxygen dissociation is particu-
larly marked at low partial pressures of oxygen (Beddell et al,
1984). Hence delivery of oxygen to hypoxic tissues will be most
effected by BW12C, and this reduction in oxygen delivery will be
much greater than is proportional to the difference in oxygen pres-
sures between hypoxic and normoxic tissues. Tumours have areas
of significant hypoxia compared to normal tissues. This is thought
to contribute to chemo- and radioresistance (Adams et al, 1997).
Mitomycin C (MMC) is a cytotoxic agent which is active in
gastrointestinal cancer. Under reducing conditions it forms alkyl-
ating metabolites that produce DNA cross-links (Sartorelli et al,
1994). In vitro, the cytotoxic activity of MMC is increased by
hypoxia (Sartorelli et al, 1994). Combining such a bioreductively
activated agent with BW12C could enable relative targeting
of hypoxic tumours. Tumour xenograft data show that BW12C
increases the cytotoxic activity of various bioreductively activated
drugs (Cole and Robbins, 1989). In addition, BW12C can protect
normal tissue from radiation damage, and mimic hypoxically
induced necrosis in certain tumours (Adams et al, 1986; Honess
et al, 1992). These effects are presumed secondary to effects on
tissue oxygenation.
Because of the possibility that BW12C could potentiate the
cytotoxicity of MMC, we performed a phase I study of BW12C in
combination with MMC in patients with advanced cancer (Philip
et al, 1993). Patients received a bolus loading dose of BW12C
over 1 h, followed by a maintenance infusion of 4 mg kg–1 h–1 for
5 h to prolong the duration of the shift in OSC. MMC 10 mg m–2
was administered over 15 min immediately after the end of the
bolus of BW12C. The dose-limiting toxicities were myocardial
ischaemia and reductions in conscious level. Other toxicities were
headache, nausea/vomiting, sinus tachycardia and vein pain.
These toxicities were dose-dependent. The maximum tolerated
dose (MTD) of BW12C was 50 mg kg–1 over 1 h.
Pharmacokinetic analysis provided no evidence that BW12C
affected plasma MMC levels. We observed changes in the haemo-
globin electrophoretic profile consistent with BW12C-oxyhaemo-
globin complexing, and a dose-related left-shift of the OSC of
above 40% at the top dose level. Phosphorus magnetic resonance
spectroscopy (31P MRS) of exercising calf muscle showed that
BW12C treatment increased the breakdown of high energy
phosphate stores and reduced pH, consistent with tissue hypoxia.
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Summary BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) stabilizes oxyhaemoglobin, causing a reversible left-shift of the oxygen
saturation curve (OSC) and tissue hypoxia. The activity of mitomycin C (MMC) is enhanced by hypoxia. In this phase II study, 17 patients with
metastatic colorectal cancer resistant to 5-fluorouracil (5-FU) received BW12C and MMC. BW12C was given as a bolus loading dose of
45 mg kg–1 over 1 h, followed by a maintenance infusion of 4 mg kg–1 h–1 for 5 h. MMC 6 mg m–2 was administered over 15 min immediately
after the BW12C bolus. The 15 evaluable patients had progressive disease after a median of 2 (range 1–4) cycles of chemotherapy.
Haemoglobin electrophoresis 3 and 5 h after the BW12C bolus dose showed a fast moving band consistent with the BW12C-oxyhaemoglobin
complex, accounting for approximately 50% of total haemoglobin. The predominant toxicities – nausea/vomiting and vein pain – were mild
and did not exceed CTC grade 2. Liver 31P magnetic resonance spectroscopy of patients with hepatic metastases showed no changes
consistent with tissue hypoxia. The principle of combining a hypoxically activated drug with an agent that increases tissue hypoxia is clinically
feasible, producing an effect equivalent to reducing tumour oxygen delivery by at least 50%. However, BW12C in combination with MMC for
5-FU-resistant colorectal cancer is not an effective regimen. This could be related to drug resistance rather than a failure to enhance
cytotoxicity. © 2000 Cancer Research Campaign
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The aim of this phase II trial was to determine tumour response
rates to BW12C in combination with MMC in patients with
advanced colorectal cancer, and to further examine the toxicity of
the regimen. Levels of BW12C-oxyhaemoglobin complex were
measured as an indirect assessment of tissue oxygen delivery.
In addition, patients underwent 31P MRS of liver metastases, to
determine whether BW12C could induce tumour hypoxia.
PATIENTS AND METHODS
Eligibility criteria
Eligibility criteria for entry included: histologically or cytologi-
cally proven colorectal carcinoma with liver metastases and
evidence of disease progression, Eastern Co-operative Oncology
Group (ECOG) performance status of 0–2, life expectancy of at
least 3 months, presence of measurable or evaluable disease,
haemoglobin greater than 10 g dl–1, white cell count greater than
3.5 ´ 109 L–1, platelet count greater than 100 ´ 109 L–1, normal
renal function and adequate hepatic function with bilirubin less
than 1.5 times normal and transaminases less than 5 times normal.
Patients were excluded if they had symptomatic ischaemic heart
disease or cerebrovascular disease, had previously received MMC
or any chemotherapy or radiotherapy within 4 weeks (6 weeks in
the case of nitrosoureas) of commencing this study. Approval to
conduct this study was granted by the Central Oxford Research
Ethics Committee and conducted according to the declaration of
Helsinki. Each patient provided written informed consent.
Drug administration
BW12C was initially administered as a single agent (cycle 1a)
followed a week later by the combination of BW12C and MMC
(cycle 1b). Thereafter BW12C and MMC were given in combina-
tion, as in cycle 1b, every 3 weeks. BW12C (Wellcome Research
Laboratories, Beckenham, UK) was administered via a controlled
intravenous (i.v.) infusion through a peripheral venous cannula. A
loading dose of BW12C – 45 mg kg–1 – was dissolved in 250 ml of
isotonic saline and infused over 1 h, followed by a maintenance
infusion of 4 mg kg–1 h–1 for 5 h in 1 litre of isotonic saline. The
loading dose was one dose increment below the MTD (50 mg kg–1)
of the phase I study (Philip et al, 1993).
Mitomycin C MMC (Kyowa; Martindale Pharmaceuticals Ltd,
Romford, UK) was administered by i.v. bolus injection of
6 mg m–2 (maximum dose 10 mg m–2) over 15 min. The injection
was given at the completion of the loading infusion of BW12C to
coincide with the peak modification of the oxygen saturation
curve (Philip et al, 1993). Anti-emetic medication comprised
metoclopramide 10 mg orally (p.o.) 4 times daily, with the
addition of dexamethasone 8 mg p.o. twice daily for 1 day
followed by 4 mg p.o. for 3 days in the event of nausea.
Assessment of toxicity
Baseline investigations included full blood count with a differen-
tial white cell count, serum biochemistry and carcinoembryonic
antigen (CEA), urinalysis, chest radiograph and electrocardio-
gram. Patients were reviewed by a physician before each cycle and
new symptoms, signs and ECOG performance status were docu-
mented. At each visit, a full blood count with differential white
count and serum biochemistry and CEA were performed.
Additional tests were performed as appropriate. National Cancer
Institute Common Toxicity Criteria (NCI-CTC) were used to
grade toxicity.
Assessment of tumour response
Evaluable and measurable disease sites were assessed before
entering the study by physical examination, plain radiography,
computerized tomography and magnetic resonance imaging where
appropriate. This was repeated every two cycles or at the time of
suspected disease progression.
Standard WHO criteria for objective response assessment were
employed. Partial responses were defined as a 50% or greater
reduction in the sum of the products of the largest perpendicular
diameters of all measurable disease sites. Progressive disease was
indicated by a greater than 25% increase in the size of at least one
measurable lesion, or the appearance of a new lesion. Stable
disease was defined as an increase in the disease measurements of
less than 25% or a decrease of less than 50%. Patients with
progressive disease were withdrawn from the study.
Haemoglobin electrophoresis
In our phase I study (Philip et al, 1993), BW12C treatment
produced a dose-dependent left-shift in the OSC, and concomitant
haemoglobin electrophoresis showed a fast running band
consistent with the BW12C-oxyhaemoglobin complex. Studies by
Beddell et al correlated the percentage of BW12C complexed
haemoglobin with amplitude of left-shift for the whole OSC curve
(Beddell et al, 1984). This provides data on effects on haemo-
globin oxygen saturation for the physiological range of oxygen
partial pressures, and a better estimation of physiological effects
of the compound than measurement of oxygen saturation at one
particular oxygen pressure. Haemoglobin electrophoresis was
therefore performed on samples pre-BW12C treatment and during
the maintenance infusion to demonstrate adequate BW12C-
oxyhaemoglobin binding, indicative of a biologically relevant left-
shift of the oxygen saturation curve.
Five millilitres of venous blood in an EDTA containing tube
was obtained immediately before administering BW12C and
repeated at 3 and 5 h from the start of the loading infusion.
Sampling was performed during cycles 1a and 1b. Haemoglobin
electrophoresis was performed using a standard technique
(Lehmann and Huntsman, 1966). Briefly, a lysate was obtained by
washing the whole blood in isotonic saline and adding carbon
tetrachloride. The lysate was then applied on a cellulose acetate
strip. After complete separation, strips were stained with Ponceau
S (BDH, Dorset, UK) and the excess stain was removed by immer-
sion in 3% acetic acid. Spectrophotometry was used to evaluate
the percentage of BW12C-oxyhaemoglobin complex relative to
the total haemoglobin.
Magnetic resonance methods
The 31P MR spectrum of the liver contains signals from ATP and
other nucleotides, inorganic phosphate (Pi), phosphomonoester
(PME) and phosphodiester (PDE). Information about the energy
metabolism is obtained from the relative intensities of the ATP and
Pi signals, together with the pH, which can be measured from the
relative frequency of the Pi signal. If BW12C causes sufficient
hypoxia in the liver that the cells cannot meet their energy needs,1778 DJ Propper et al
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the Pi:ATP ratio should increase, and the pH decrease. Information
about carbohydrate and lipid metabolism can be obtained from the
other signals. The PME signal contains contributions from AMP,
phosphorylated sugars, and other intermediates of carbo-
hydrate, lipid and phospholipid metabolism (including phospho-
ethanolamine and phosphocholine). Tumours contain a prominent
PME signal, which has been found to consist largely of phospho-
ethanolamine (Negendank, 1992), and may signify differences in
phospholipid metabolism in tumour cells. The PDE signal in the
liver comes mainly from phospholipid bilayers, but also contains
contributions from glycerophosphocholine (GPC) and glycero-
phosphoethanolamine (GPE), which are breakdown products
of phospholipids.
Localized MR spectra were obtained as previously described
(Dixon et al, 1992), using a modification of the phase modulated
rotating frame imaging technique. The spectra were obtained
on a 1 m bore, 2.0 T superconducting magnet (Oxford Magnet
Technology, Oxford, UK) interfaced to an Avance spectrometer
(Bruker, Coventry, UK) operating at 34 MHz for phosphorus. Each
patient was positioned so that the liver was over the coil centre.
Metabolite levels were measured with a double surface coil in
which the receiver coil (7 cm diameter) was placed forward of, and
isolated from the transmitter coil (15 cm diameter). An interpulse
delay of 2 s was used, and a pulse width of 90° in the liver. The
phosphorus image took 17 min to collect, and the whole study
completed in 30–40 min.
After Fourier transformation, the 31P MR image consisted of
spectra from disc-shaped regions parallel to the surface coil, and at
increasing depths into the body. Although the exact volume of
tissue that gave rise to the signal in a particular row of the image
was not known, the receiver coil was small enough in diameter to
ensure that the liver covered the entire sensitive volume of the coil.
A row from approximately 1 cm into the liver was selected for
quantification. Metabolite signal areas were measured by fitting
the signals to Lorentzian and Gaussian lines, after baseline correc-
tion. The signal from ATP (g-P) was used to measure ATP since
the ATP (b-P) signal was distorted by off-resonance effects, and
the ATP (a-P) is known to contain contributions from other
metabolites.
Patients underwent MRS studies as follows: study 1: pre-infu-
sion (either the day before, or the morning of the first infusion).
Study 2: started within 1 h of end of BW12C infusion. Study 3: 1
week later, started within 1 h of end of BW12C+MMC infusion.
Study 4: 1–2 weeks later, control study.
Statistical analysis
To ensure a low probability of rejecting a treatment that is active in
20% of patients, at least 14 patients were treated, according to
previously described principles (Gehan, 1961). Comparison of
haemoglobin electrophoresis data was performed by paired t-tests.
Data from the MRS studies were compared by paired t-tests and
one-way analysis of variance.
RESULTS
Seventeen patients with hepatic metastases from a colorectal
primary entered the study. All patients had previously received
chemotherapy with 5-FU, given in a variety of different regimens.
Six patients were treated in the adjuvant setting, one of whom
progressed on treatment. Eleven patients were treated for
metastatic disease with no objective responses, five patients had
stable disease (lasting for between 1 and 6 months after their final
cycle of 5-FU) and six progressed. In addition, five patients had
received radiotherapy, four as adjuvant treatment to the pelvis and
one to pelvic disease. The patient characteristics are shown in
Table 1.
Responses
Of 17 patients treated, 15 were evaluable for disease response.
Two patients could not be evaluated. One died suddenly 20 days
following cycle 1b and one was withdrawn from the study due to
toxicity (grade II fever) after cycle 2. This patient continued treat-
ment with MMC alone and the temperature did not recur. There
were no responses to treatment and all 15 evaluable patients
stopped treatment because of progressive disease. The median
number of treatment cycles was 2 (range 1–4).
Toxicity
The toxicities associated with treatment are shown in Table 2. Vein
pain (grade I) occurred in all patients during the loading dose infu-
sion, while the BW12C was administered at high concentration.
The pain started around 10 min into the infusion in the cannulated
vein, was spasmodic in nature and stopped when the loading dose
was finished. No patients experienced vein pain during the mainte-
nance infusion, nor were there any signs of phlebitis. One patient
came off study after cycle 1b following a pulmonary embolism
diagnosed on ventilation/perfusion scanning which presented as
moderate dyspnoea and right sided lower chest pain. Two patients
Table 1 Patient characteristics
Total number treated 17
Median age in years (range) 56 (37–67)
Male/Female 10/7
Site of primary
Colon 10
Rectum 7
Previous treatment
Surgical resection 16
5-FU chemotherapy 17 (6 adjuvant)
Radiotherapy 5
ECOG performance status
(No. of patients) 0 (12)
1 (5)
Table 2 Toxicities associated with treatment
CTC grade 1 2 3 4
Vein pain 17 0 0 0
Thromboembolism 0 0 0 1
Fever 0 2 0 0
Altered taste 3 0 0 0
Headache 4 0 0 0
Fatigue 7 0 0 0
Nausea/vomiting 8 1 0 0
Diarrhoea 1 2 0 0
Mucositis 1 0 0 0
Musculoskeletal pain 2 0 0 0
Maximal grade toxicities shown.developed fevers above 39°C, one during and one shortly following
the BW12C infusion in cycle Ib. In both patients the fever settled
overnight, however, one of these patients also had rigors and both
the pyrexia and rigors recurred following the second cycle. The
patient was therefore withdrawn from the study.
Other toxicities included grade 1 headache, grade 1 fatigue and
transient nausea/vomiting, as observed in the phase I study. The
dose-limiting toxicities from the phase I study (myocardial
ischaemia and altered conscious level) was not observed, neither
was tachycardia, also seen in the earlier study. One patient experi-
enced mild chest pain after the end of the BW12C infusion (cycle
Ia), lasting 15 min. The pain was musculoskeletal rather than
cardiac in nature. There were no associated symptoms or signs of
cardiac ischaemia and electrocardiograms before and during a
subsequent cycle were normal. Another patient described 24 h of
backache after cycle 1b. Mucositis (one patient), altered taste
and diarrhoea (three patients each), also occurred but were mild
(grade ≤ 2).
Haemoglobin electrophoresis
Haemoglobin electrophoresis studies were performed in eight
patients (Table 3). No abnormal haemoglobins were observed in
the baseline pre-BW12C treatment samples. A fast moving band
was observed in all samples obtained 3 and 5 h after the start of the
loading infusion, consistent with the BW12C-oxyhaemoglobin
complex (Philip et al, 1993). This accounted for above 50% of the
total haemoglobin after 3 and 5 h of treatment (Table 3). There
were no significant differences in the percentage of complexed
haemoglobin at 3 and 5 h, between cycles 1a and 1b, nor between
the 3 and 5 h samples obtained during the same cycle.
Magnetic resonance spectroscopy
Eight patients were studied, five had hepatic metastases from
colorectal primaries, and three with hepatic metastases from other
tumour types (Table 4). These three patients were treated as per
protocol. Eight patients took part in studies 1 and 2; six went on to
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Table 3 Percentage oxyhaemoglobin-BW12C complex with BW12C
treatment
3h 5h
Treatment
cycle Range Mean s.d. Range Mean s.d.
1a 41.0–69.1 54.4 9.8 42.5–60.0 53.4 6.1
1b 53.8–61.9 57.9 2.6 46.1–61.9* 55.8 5.8
s.d., Standard deviation. Haemoglobin electrophoresis was performed in
eight patients for each time point except * at which there were 7. No
complexed haemoglobin was seen at time zero. The table shows the
percentage of oxyhaemoglobin-BW12C complex to total haemoglobin at 3
and 5 h after the start of the loading infusion of BW12C in cycles 1a and 1b.
There were no significant differences in the percentage of complexed
haemoglobin either between time points within a cycle or between cycles at
the 3 or 5 h time points.
Table 4 Subject details for associated MRS study
Patients Controls
Number of subjects 8 10
Median age in years (range) 54 (28–67) 35 (20–72)
Male/Female 6/2 5/5
Site of primary
Colorectal 5
Breast 2
Lung (squamous) 1
Table 5 Mean values of metabolite ratios for the 31P MRS liver studies
Study 1 s.d. Study 2 s.d. Study 3 s.d. Study 4 s.d.
PME/ATP 0.82 0.23 0.86 0.33 0.81 0.12 0.94 0.31
Pi/ATP 0.72 0.12 0.68 0.21 0.66 0.12 0.76 0.13
PDE/ATP 1.79 0.35 1.76 0.36 1.92 0.26 1.82 0.38
PME/PDE 0.46 0.11 0.51 0.24 0.42 0.04 0.51 0.07
No. of subjects 8 8 6 4
Controls s.d. Significance compared to study 1
(ANOVA)
PME/ATP 0.61 0.15 0.036
Pi/ATP 0.71 0.10 0.840
PDE/ATP 1.66 0.19 0.342
PME/PDE 0.37 0.09 0.049
No. of subjects 10
PME, phosphomonoester; Pi, inorganic phosphate, PDE, phosphodiester; ATP, adenosine triphosphate. s.d., Standard deviation. Study 1: pre-infusion (either
the day before, or the morning of the first infusion); Study 2: started within 1 h of end of BW12C infusion; Study 3: 1 week later, started within 1 h of end of
BW12C + MMC infusion; Study 4: 1–2 weeks later, control study. The metabolite ratios provide information about the metabolic activity within the liver; the
PME/ATP and PME/PDE ratios are thought to relate to the amount of tumour in the liver, and the Pi/ATP ratio gives an indication of the energetic status of the
liver. The PDE/ATP ratio reflects the amount of endoplasmic reticulum within the liver. There were no significant differences in any of the metabolite ratios
between any of the patient studies, but the PME/ATP and PME/PDE ratios were significantly higher in the patients than in controls.1780 DJ Propper et al
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study 3 and four patients completed all four studies. Ten control
subjects (Table 4) were also studied by the same MRS protocol
(Table 5).
For the patient group, there were no significant changes in any
of the measured parameters from one study to the next, either as a
group or on an individual basis (that is, there was no trend for the
patients’ metabolite ratios to increase or decrease between partic-
ular studies). Neither was there any change in pH, as calculated
from the frequency of the Pi signal, relative to the ATP (a-P)
signal. In comparison to the control group, the only significant
differences were in the PME/ATP and PME/PDE metabolite
ratios, both of which were elevated in patients.
DISCUSSION
In this phase II study of combined MMC and BW12C treatment,
there were no disease responses. Neither was there other evidence
that the drug combination modified tumour growth, such as a high
incidence of stable disease after treatment. All the patients had
previously received 5-FU-based chemotherapy. Responses to
MMC as a second line agent after 5-FU are likely to be low. This is
suggested by several randomized comparisons of 5-FU to 5-FU
plus MMC for treating colorectal cancer which failed to show
additive effects (Buroker et al, 1978; Richards et al, 1986),
although a small additive effect on response rather than survival
was reported (Ross et al, 1997). However, only one response was
observed in 72 patients treated with MMC after 5-FU in phase II
trials (Hartmann et al, 1998; Migeod et al, 1988; Zaniboni et al,
1995). The current study was therefore a stringent test of the
MMC/BW12C combination. Nonetheless, in a phase I trial of
BW12C + MMC, 2/26 patients with advanced gastrointestinal
cancer attained disease responses (Dennis et al, 1993).
There are at least two reductive pathways by which MMC is
activated. The first pathway includes P450 reductase and the
second, DT-diaphorase (Mikami et al, 1996). Colon cancer cell
lines, mainly from the National Cancer Institute (NCI) human
tumour cell panel, generally had high DT-diaphorase levels
(Fitzsimmons et al, 1996). The sensitivity of tumour cell lines
to MMC correlates with levels of these enzymes, particularly
DT-diaphorase (Fitzsimmons et al, 1996; Mikami et al, 1996).
However, under hypoxic conditions, DT-diaphorase-rich HT29
cells showed little hypoxic sensitization to mitomycin C (Plumb
and Workman, 1994). Furthermore, it is possible that there was
insufficient tumour hypoxia to activate MMC, since there are data
showing that very marked hypoxia is required to augment MMC
cytotoxicity (Brown, 1998). These factors might explain why,
despite the possibility of increased tumour hypoxia using BW12C,
responses to MMC were not observed.
The aim of this study was to augment MMC activation selec-
tively within the tumour. Haemoglobin electrophoresis showed a
fast running BW12C-oxyhaemoglobin band that accounted for a
mean of over 50% of the total haemoglobin during the time of
BW12C administration. Data from the earlier phase I study indi-
cate that this degree of binding will have been sufficient to cause
left shifting of the OSC over 5 half-lives of MMC and therefore
maintained for over 95% of the exposure to MMC (Philip et al,
1993). There was no significant difference in the percentage of
complexed haemoglobin at 3 and 5 h, between cycles 1a and 1b,
indicating that the process is not affected by MMC. The effect
of BW12C on tissue oxygen delivery is dependent on the partial
pressure of oxygen, and is most marked at low oxygen pressures
(Beddell et al, 1984). Hypoxia in tumours varies, and although not
defined in colorectal tumours clinically, would be expected to be
around 1.5 kPa (Brizel et al, 1997). Based on correlations between
BW12C-oxyhaemoglobin levels and oxygen saturation, the degree
of BW12C-oxyhaemoglobin complexing observed in this study
would be associated with at least a 50% reduction in oxygen
delivery to hypoxic tissues, and this percentage reduction in
oxygen delivery would rise much more than proportionally as the
degree of tumour hypoxia increases (Beddell et al, 1984). This is a
function of the sigmoid shape of the OSC. Hence, at least theoreti-
cally, hypoxic areas of tumours would have been rendered
intensely hypoxic, whereas relatively normoxic tissue would have
been much less affected by BW12C.
BW12C induces tissue hypoxia and necrosis, as well as radio-
resistance. Although these effects are presumed secondary to
effects of the drug on the OSC, there is evidence that these effects
could in part be mediated by BW12C-induced reductions in
tumour blood flow. Falk et al showed that the hypoxic effect of
BW12C could be due to a reduction in tumour blood flow rather
than hypoxia per se (Falk et al, 1994). They also suggested that the
radio-protective effect of BW12C was due to reduced tumour
perfusion. Others have also shown that BW12C can reduce tissue
perfusion (Honess et al, 1991). If BW12C does reduce tumour
blood flow, any bio-reductive effect on MMC would be countered
by reduced drug delivery. This could provide another explanation
for the absence of tumour effects observed in the current study.
The toxicities in this study were low. All patients developed
vein pain, which is related to drug concentration in the loading
solution (Philip et al, 1993). Other side-effects were headache,
fatigue and nausea/vomiting, which did not exceed CTC grade II
toxicity levels. One patient aged 36 died suddenly 20 days after
cycle 1b. The cause of death was unknown, but if due to myocar-
dial infarction it seems unlikely that BW12C contributed to this
because its effect on the OSC is short (Fitzharris et al, 1985), and
in our previous study we showed that the haemoglobin band
consistent with the BW12C-oxyhaemoglobin complex had disap-
peared the day after treatment (Philip et al, 1993). There was no
evidence of myocardial ischaemia or alteration in conscious state,
which were the dose-limiting toxicities in the phase I study. Nor
was there any haematological toxicity, or mucositis. Hence there
was no evidence that BW12C potentiates MMC toxicity.
The 31P MR spectra of the patients’ livers showed no significant
changes between the studies, either when mean values for the
whole patient group were compared, or when the individual
changes were compared in a pairwise fashion. We saw no bio-
energetic changes, as assessed from the Pi/ATP ratio and the pH,
between the initial studies, and the studies immediately following
infusion of BW12C with or without MMC. The Pi/ATP ratio was
not significantly different from the same ratio in healthy controls.
This indicates that BW12C did not significantly alter the energetic
status of the liver. This is perhaps surprising, given that the ener-
getics of muscle was altered by this drug (Philip et al, 1993), but
may be explained by the fact that the changes in muscle were seen
after exercise and not in the resting muscle, and we were effec-
tively looking at the ‘resting’ liver, in that it had not been stressed
by, for instance, administering a metabolic load (e.g. fructose). In
addition and as discussed, because of the sigmoid shape of the
OSC, BW12C induces most hypoxia in areas that are already
hypoxic. The liver has a large blood supply, which may haveincreased to compensate for any shortage of oxygen. Also ATP
levels can be maintained under hypoxic conditions by a variety of
mechanisms (Hochachka et al, 1996)
There were no significant changes in the ratios of PME to any
other metabolite following the infusions, which suggests that there
was no change of the amount of tumour in the volume of liver
sampled. The PME/ATP and PME/PDE ratios in patients were
significantly higher than in control subjects, confirming that MRS
could detect hepatic metastases. The PME signal is much greater
in tumours than in normal liver (Negendank, 1992), and so the
signal from PME in the spectra will largely reflect the amount of
tumour in the volume sampled. The PME signal in many tumours
has been found to be largely composed of phosphoethanolamine,
which is a precursor of phospholipids in membranes (Ruiz-Cabello
and Cohen, 1992; Dixon, 1996). It is not known why phospho-
ethanolamine reaches high concentrations (several millimolar) in
tumours, but it seems to be generally increased in rapidly dividing
tissue, including the regenerating liver. It has been found in a
number of studies (Dixon et al, 1991; Negendank, 1992) that
following chemotherapy the PME signal of tumours decreases in
tumours responding to the therapy. The fact that the PME/ATP and
PME/PDE ratios in this study did not alter significantly therefore
suggests that the metastatic tumours in the liver did not respond to
BW12C and MMC therapy, which is in keeping with the clinical
course of the patients.
The current study, and our previous phase I data indicate that the
principle of combining a hypoxically activated drug with an agent
that stabilizes the OSC to increase tissue hypoxia is clinically
feasible, achieves biological effects on tissue oxygen delivery and
does not cause undue toxicity. The absence of tumour responses
seems likely to be due to the population of patients studied,
although there is a possibility that an effect of BW12C in reducing
tumour perfusion counters any bioreductive effect. It is also
possible that there was insufficient hypoxic activation of MMC.
Studies combining BW12C with drugs such as AQ4N and tira-
pazamine (Patterson, 1993; Workman and Stratford, 1993) which
have a much higher hypoxic:normoxic ratio of activity would be of
considerable interest. If feasible, measurement of tumour
levels of enzymes involved in drug bioreduction would provide
additional insight on efficacy.
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